We are the creator of Viaskin®

We are a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.

Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®.

DBV Technologies is advancing this unique technology to improve the lives of infants and children suffering from severe food allergies. For these patients, safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, including anaphylactic shock.